gemfibrozil has been researched along with Coronary Artery Disease in 27 studies
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, the area under the curve, maximum plasma concentration, and time to maximum concentration for fluvastatin and gemfibrozil are compared, when used alone and in combination, in patients with hyperlipidemia and either coronary or carotid atherosclerosis, or a family history of coronary artery disease." | 5.08 | Pharmacokinetics of the combination of fluvastatin and gemfibrozil. ( Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD, 1995) |
| "Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis." | 2.71 | Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. ( Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB, 2003) |
| "Gemfibrozil therapy was associated with a median 18% increase in tHcy levels (P < 0." | 2.71 | Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. ( Frick, MH; Humphries, SE; Kesäniemi, YA; Nieminen, MS; Pasternack, A; Syvänne, M; Taskinen, MR; Turpeinen, U; Whittall, RA, 2004) |
| "The progression of coronary atherosclerosis was estimated by quantitative, computer-assisted analysis of coronary artery stenoses from the baseline angiograms and from repeated angiograms performed an average of 32 months later." | 2.69 | Heart rate variability and progression of coronary atherosclerosis. ( Airaksinen, KE; Frick, MH; Huikuri, HV; Ikäheimo, MJ; Jokinen, V; Kauma, H; Kesäniemi, AY; Koistinen, JM; Majahalme, S; Niemelä, KO; Nieminen, MS; Syvänne, M, 1999) |
| "Lipid-lowering therapy ameliorates coronary atherosclerosis in patients with raised concentrations of low-density-lipoprotein (LDL) cholesterol." | 2.67 | Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. ( Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH, 1994) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), in which subjects were randomized to treatment with lovastatin or placebo, also reported a striking benefit of treatment, particularly in patients with HDL-C < or =35 mg/dL at baseline." | 2.41 | High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. ( Boden, WE, 2000) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| "Gemfibrozil has shown beneficial effects as a lipid lowering agent; however, some proactivating effects on platelet function in vitro have been described." | 1.30 | Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk. ( Alfón, J; Badimon, L; Berrozpe, M; Gaffney, P; Palazón, CP; Royo, T, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 15 (55.56) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Song, H | 1 |
| Bai, J | 1 |
| Xiu, J | 1 |
| Wu, G | 1 |
| Zhang, L | 1 |
| Wu, Y | 1 |
| Qu, Y | 1 |
| Rembold, CM | 1 |
| Devendra, GP | 1 |
| Whitney, EJ | 1 |
| Krasuski, RA | 1 |
| Kar, S | 1 |
| Chockalingam, A | 1 |
| Talmud, PJ | 2 |
| Martin, S | 1 |
| Steiner, G | 1 |
| Flavell, DM | 2 |
| Whitehouse, DB | 1 |
| Nagl, S | 1 |
| Jackson, R | 1 |
| Taskinen, MR | 6 |
| Frick, MH | 8 |
| Nieminen, MS | 7 |
| Kesäniemi, YA | 6 |
| Pasternack, A | 6 |
| Humphries, SE | 3 |
| Syvänne, M | 7 |
| Després, JP | 1 |
| Lemieux, I | 1 |
| Pascot, A | 1 |
| Alméras, N | 1 |
| Dumont, M | 1 |
| Nadeau, A | 1 |
| Bergeron, J | 1 |
| Prud'homme, D | 1 |
| Viles-Gonzalez, JF | 1 |
| Fuster, V | 1 |
| Corti, R | 1 |
| Badimon, JJ | 1 |
| Whittall, RA | 1 |
| Turpeinen, U | 1 |
| Barter, PJ | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Spence, JD | 1 |
| Munoz, CE | 1 |
| Hendricks, L | 1 |
| Latchinian, L | 1 |
| Khouri, HE | 1 |
| Sacks, FM | 1 |
| Pasternak, RC | 1 |
| Gibson, CM | 1 |
| Rosner, B | 1 |
| Stone, PH | 1 |
| Havel, RJ | 1 |
| Kauma, H | 3 |
| Majahalme, S | 3 |
| Virtanen, V | 2 |
| Palazón, CP | 1 |
| Alfón, J | 1 |
| Gaffney, P | 1 |
| Berrozpe, M | 1 |
| Royo, T | 1 |
| Badimon, L | 1 |
| Ehnholm, C | 2 |
| Huikuri, HV | 1 |
| Jokinen, V | 1 |
| Airaksinen, KE | 1 |
| Ikäheimo, MJ | 1 |
| Koistinen, JM | 1 |
| Kesäniemi, AY | 1 |
| Niemelä, KO | 1 |
| Granberry, MC | 1 |
| Smith, ES | 1 |
| Talley, JD | 1 |
| Krakoff, J | 1 |
| Vela, BS | 1 |
| Brinton, EA | 1 |
| Rubins, HB | 1 |
| Boden, WE | 1 |
| Karpe, F | 1 |
| Hamsten, A | 1 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Nyman, JA | 1 |
| Martinson, MS | 1 |
| Nelson, D | 1 |
| Nugent, S | 1 |
| Collins, D | 1 |
| Wittes, J | 1 |
| Fye, CL | 1 |
| Wilt, TJ | 1 |
| Robins, SJ | 1 |
| Bloomfield Rubins, H | 1 |
| Jamshidi, Y | 1 |
| Hawe, E | 1 |
| Pineda Torra, I | 1 |
| Staels, B | 1 |
| Miller, G | 1 |
| Jauhiainen, M | 1 |
| Koskinen, P | 1 |
| Mänttäri, M | 1 |
| Manninen, V | 1 |
| Huttunen, JK | 1 |
| Kashyap, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000461] | Phase 2 | 0 participants | Interventional | 1986-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for gemfibrozil and Coronary Artery Disease
| Article | Year |
|---|---|
Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.
Topics: Acute Kidney Injury; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Gemfibro | 2013 |
Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.
Topics: Animals; Cholesterol, HDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Endotheli | 2003 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Gemfibro | 2000 |
Triglycerides and coronary heart disease: implications of recent clinical trials.
Topics: Aged; Bezafibrate; Controlled Clinical Trials as Topic; Coronary Artery Disease; Female; Gemfibrozil | 2000 |
High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Female; Gemfibr | 2000 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
Basic considerations in the reversal of atherosclerosis: significance of high-density lipoprotein in stimulating reverse cholesterol transport.
Topics: Age Factors; Aged; Biological Transport; Cholesterol; Cholesterol, HDL; Coronary Artery Disease; Gem | 1989 |
11 trials available for gemfibrozil and Coronary Artery Disease
| Article | Year |
|---|---|
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholestyramine Res | 2010 |
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino A | 2003 |
Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
Topics: Adult; Body Constitution; C-Reactive Protein; Coronary Artery Disease; Gemfibrozil; Humans; Hyperlip | 2003 |
Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.
Topics: Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind M | 2004 |
Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Stenosis; Coronary Artery Disease; Coronary Dise | 1995 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; | 1994 |
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
Topics: Aged; Analysis of Variance; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coron | 1997 |
Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Topics: Apolipoproteins; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Bypass; Corona | 1998 |
Heart rate variability and progression of coronary atherosclerosis.
Topics: Analysis of Variance; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Disease Progr | 1999 |
Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment.
Topics: Apolipoproteins; Cholesterol; Constriction, Pathologic; Coronary Artery Disease; Double-Blind Method | 2001 |
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Cost-Benefit Analysis; Gemfibrozi | 2002 |
8 other studies available for gemfibrozil and Coronary Artery Disease
| Article | Year |
|---|---|
Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states.
Topics: Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Gemfibrozil; Glucose; Humans; Hype | 2023 |
To statin or to non-statin in coronary disease-considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Aci | 2008 |
Antiatherogenic properties of fibrates.
Topics: Animals; Coronary Artery Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Risk Factors | 2005 |
Benefits of fibrate drugs in coronary heart disease patients with normal cholesterol levels.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Diseas | 1997 |
Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Fibrin; Gemf | 1998 |
Raising HDL-C to prevent atherosclerotic events.
Topics: Cholesterol, HDL; Coronary Artery Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle A | 2000 |
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Topics: Aged; Alleles; Amino Acid Substitution; Arteriosclerosis; Clinical Trials as Topic; Cohort Studies; | 2002 |
Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.
Topics: Adult; Case-Control Studies; Coronary Artery Disease; Finland; Gemfibrozil; Humans; Lipids; Lipoprot | 1991 |